Skip to main navigation Skip to search Skip to main content

The APROVE (Anti-coagulation/Platelet Treatment in Pancreatic Resections Involving Vascular Reconstruction) Study: Results from a Worldwide Survey

  • Alessio Marchetti*
  • , Jonathan Garnier
  • , Joseph R. Habib
  • , Ingmar F. Rompen
  • , Paul C.M. Andel
  • , Camila Hidalgo Salinas
  • , Molly Ratner
  • , Matteo De Pastena
  • , Roberto Salvia
  • , D. Brock Hewitt
  • , Katherine Morgan
  • , Michael D. Kluger
  • , Karan Garg
  • , Ammar A. Javed
  • , Christopher L. Wolfgang
  • , Greg D. Sacks
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Background: Antithrombotic therapy (AT) aims to strike a balance between preventing thromboembolic and hemorrhagic complications. However, evidence for AT management after pancreatectomy with vascular reconstruction is lacking. We aimed to provide an overview of the current use of AT for pancreatic surgery with vascular reconstructions. Patients and Methods: A web-based survey was distributed to 123 surgeons from high-volume pancreas centers (>50 pancreatic resections/year). AT management after different types of vascular reconstruction were investigated. An “aggressive” protocol was defined as the use of any AT protocol other than prophylactic heparin, aspirin, or their combination. Results: The survey was completed by 80 surgeons (59% Europe, 30% USA, 11% Asia). In Europe/Asia, prophylactic heparin was the most commonly reported protocol after partial venous resection/end-to-end anastomosis/human graft (71%/65%/50%, respectively), and an “aggressive” protocol (86%) was the most frequently used after prosthetic graft reconstruction. Conversely, in the USA, prophylactic heparin + aspirin was the most commonly reported protocol after all types of venous reconstruction. Following arterial reconstruction, heparin + aspirin was the most commonly reported protocol, regardless of region. An “aggressive” protocol was more frequently used in Europe/Asia (odds ratio (OR) 1.28; p < 0.001) and following vein reconstruction with either human graft (OR 1.2; p = 0.007) or prosthetic graft (OR 1.56, p <0.001), while ultrasound (OR 1.65; p < 0.001) and arterial reconstruction (OR 1.64; p < 0.001) were significantly associated with antiplatelet use. Conclusions: In an international cohort of high-volume pancreas surgeons, significant variation in the use of AT following pancreatectomy with vascular reconstruction was observed. This variation was driven by geographical differences and the type of vascular reconstructions performed. Mini Abstract: In an international cohort of high-volume pancreas surgeons, this Worldwide Snapshot Survey analyzed the current use of antithrombotic therapy for pancreatic surgery with vascular reconstruction. A significant heterogeneity in antithrombotic practice was found and it was mainly driven by geographical differences and the type of vascular reconstructions performed.

Original languageEnglish
Pages (from-to)7400–7409
Number of pages10
JournalAnnals of surgical oncology
Volume32
Issue number10
Early online date30 Jun 2025
DOIs
Publication statusPublished - 2025

Keywords

  • Anticoagulants
  • Antiplatelets
  • Antithrombotic therapy
  • Pancreatic surgery
  • Vascular reconstruction

Fingerprint

Dive into the research topics of 'The APROVE (Anti-coagulation/Platelet Treatment in Pancreatic Resections Involving Vascular Reconstruction) Study: Results from a Worldwide Survey'. Together they form a unique fingerprint.

Cite this